Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect Dis ; 193(11): 1528-35, 2006 Jun 01.
Article in English | MEDLINE | ID: mdl-16652281

ABSTRACT

BACKGROUND: Carriage of hepatitis B virus (HBV) is a major risk factor for liver cirrhosis and hepatocellular carcinoma. Infant vaccination has been effective in preventing horizontal transmission during early childhood. It is unknown whether protection is maintained into early adulthood. METHODS: In 1984, early childhood vaccination was introduced in 2 rural Gambian villages. In 2003, serological assessment of 81.5% of 1,350 eligible participants 1-24 years old was done, to determine vaccine efficacy against infection and carriage. RESULTS: Overall vaccine efficacy against infection and carriage was 83.4% (95% confidence interval [CI], 79.8%-86.6%) and 96.5% (85% CI, 93.9%-98.9%), respectively. Vaccine efficacy against infection was similar when restricted to primary responders (85.3%), but a significant effect of peak antibody concentration was found. Both vaccine efficacy and levels of hepatitis B surface antibody (anti-HBs) decreased with age, resulting in a vaccine efficacy against infection and carriage among 20-24-year-old participants of 70.9% (95% CI, 60.4%-80.5%) and 91.1% (95% CI, 75.8%-100%), respectively. Fifteen years after vaccination, fewer than half of the vaccinees had detectable anti-HBs. The prevalence of carriage in the unvaccinated population was similar to the prevalence 20 years earlier. CONCLUSIONS: HBV vaccination early during life can provide long-lasting protection against carriage, despite decreasing antibody levels. The role played by subclinical boosting and the necessity of a booster need to be evaluated.


Subject(s)
Carrier State/prevention & control , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Adolescent , Adult , Age Factors , Child , Child, Preschool , Gambia , Hepatitis B Antibodies/blood , Hepatitis B Surface Antigens/blood , Hepatitis B Vaccines/administration & dosage , Humans , Infant
2.
Parasitol Today ; 14(10): 436, 1998 Oct.
Article in English | MEDLINE | ID: mdl-17040839
3.
Diabetes ; 46(4): 599-606, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9075799

ABSTRACT

Currently there is debate regarding the capacity of pancreatic islets to regenerate in adult animals. Because pancreatic endocrine cells are thought to arise from duct cells, we examined the pancreatic ductal epithelium of the diabetic NOD mouse for evidence of islet neogenesis. We have evidence of duct proliferation as well as ductal cell differentiation, as suggested by bromodeoxyuridine-labeling and the presence of glucagon-containing cells within these ducts. In addition, the ductal epithelia in diabetic NOD mice expressed the neuroendocrine markers neuropeptide Y and tyrosine hydroxylase. These ducts also expressed the homeobox gene product, insulin promoter factor 1. Ductal cell proliferation and expression of these markers was not observed in transgenic NOD mice (NOD-E), which do not develop clinical or histopathological symptoms of IDDM. This suggests that the observed ductal cell proliferation and differentiation was a direct result of beta-cell destruction and insulin insufficiency in these adult diabetic mice, which further suggests that these events are recapitulating islet ontogeny observed during embryogenesis. It is possible that comparable processes occur in the human diabetic pancreas.


Subject(s)
Diabetes Mellitus, Type 1/physiopathology , Homeodomain Proteins , Pancreatic Ducts/physiology , Regeneration , Animals , Antimetabolites/administration & dosage , Antimetabolites/analysis , Antimetabolites/metabolism , Bromodeoxyuridine/administration & dosage , Bromodeoxyuridine/analysis , Bromodeoxyuridine/metabolism , Diabetes Mellitus, Type 1/metabolism , Disease Models, Animal , Female , Glucagon/analysis , Glucagon/immunology , Guinea Pigs , Immune Sera/immunology , Immunohistochemistry , Insulin/analysis , Insulin/immunology , Male , Mice , Mice, Inbred NOD , Neuropeptide Y/analysis , Neuropeptide Y/immunology , Pancreatic Ducts/immunology , Pancreatic Ducts/metabolism , Rabbits , Rats , Trans-Activators/analysis , Trans-Activators/immunology , Tyrosine 3-Monooxygenase/analysis , Tyrosine 3-Monooxygenase/immunology
4.
J Pathol ; 165(1): 75-80, 1991 Sep.
Article in English | MEDLINE | ID: mdl-1659628

ABSTRACT

A quantitative immunocytochemical study of large granular lymphocytes (LGLs) in the normal cervix and in human papillomavirus (HPV) associated disease was performed using a panel of monoclonal antibodies which included those for LGL surface markers CD56, CD16, and CD57. Only CD56-positive cells were found within the ectocervical epithelium and these cells increased in number in cervical intraepithelial neoplasia (CIN) in comparison with normal cervix. Examination of serial sections and double labelling suggests that these cells are CD3+, CD8+, CD56+, CD16+. The observed increase in number of this subset was not associated specifically with HPV infection but was related to CIN. Lymphocytes expressing all three LGL markers were found in the stroma and CD16(+)-positive cells clustered around endocervical glands with occasional cells extending into the endocervical epithelium. These results indicate that a small subset of LGLs which express T-cell markers is increased in number in CIN. Cells expressing classical NK markers are restricted to the stroma and are not found within the ectocervical epithelium.


Subject(s)
Cervix Uteri/pathology , Lymphocytes/pathology , Papillomaviridae , Tumor Virus Infections/pathology , Uterine Cervical Neoplasms/pathology , Adult , Antigens, CD/analysis , Epithelium/pathology , Female , Humans , Leukocyte Count , Mathematics
SELECTION OF CITATIONS
SEARCH DETAIL
...